Business Context and Reporting Period
Pliant Therapeutics, Inc. filed a Form 8-K reporting that, on February 17, 2023, it received notice from Novartis Institutes for BioMedical Research, Inc. that Novartis elected to terminate their Collaboration and License Agreement, as amended. The termination becomes effective April 18, 2023.
The collaboration involved PLN-1474, an investigational small-molecule integrin αvβ1 inhibitor for liver fibrosis associated with nonalcoholic steatohepatitis (NASH), and research programs covering up to three additional integrin targets.
Financial and Operating Metrics
| Item | Reported information |
|---|---|
| Upfront license fee | $50.0 million, non-refundable |
| Contingent payments | Up to $416.0 million; $29.0 million received as of the filing |
| Future milestones, royalties, and R&D funding | Novartis payment obligations terminate upon effectiveness of the agreement termination |
| Revenue, profit, cash flow, margins, debt, and liquidity | The filing text does not provide clear values for these metrics |
Material Changes Versus the Prior Comparable Period
- Novartis is discontinuing development of PLN-1474 and is divesting clinical NASH assets as part of a strategy focused on a limited number of therapeutic areas.
- Upon termination, all rights and licenses granted to Novartis, including rights to PLN-1474, its related investigational new drug application, and development candidates targeting the validated research target, will revert to Pliant.
- The research term for the additional targets was scheduled to conclude in the first quarter of 2023.
- Pliant successfully validated one research target and synthesized multiple potential development candidates in the second quarter of 2022.
Outlook, Risks, and Unusual Items
- Pliant will regain rights to the relevant programs but will also lose future milestone, royalty, and research and development funding opportunities from Novartis.
- The filing does not provide updated development timelines, financing plans, clinical prospects, or cost estimates for continued development of the returned assets.
- The termination reflects a strategic decision by Novartis and does not, in the filing, identify a specific safety or efficacy concern regarding PLN-1474.
- The agreement termination is effective April 18, 2023, rather than on the notice date.
Investor Verification Items
- Verify the accounting and expected timing of any effects from the termination in Pliant’s annual and subsequent quarterly filings.
- Assess whether Pliant intends to continue, partner, or discontinue development of PLN-1474 and the returned research programs.
- Review the company’s liquidity and financing needs because future Novartis funding and milestone payments will terminate.
- Confirm the precise rights, obligations, and effective termination provisions in the Collaboration Agreement and Amendment No. 1.
- Monitor whether the returned assets generate impairment charges, restructuring costs, or new research and development commitments.